Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808 in Healthy Adult Subjects and in Adults With Cystic Fibrosis

NCT03251092 is registered in ClinicalTrials.gov with Proteostasis Therapeutics, Inc. as lead sponsor.

NCT NCT03251092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03251092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PTI-808 in Healthy Adult Subjects and in Adults With Cystic Fibrosis
Lead sponsor
Proteostasis Therapeutics, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 17, 2017
Completion date
December 23, 2019
Enrollment
179 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

cystic fibrosis - complete, healthy volunteer - complete